Symposium:
26. Invasive Fungal Infections in Children
Thursday, October 18, 2012: 8:30 AM-10:00 AM
Room: SDCC 33 ABC
Developed in collaboration with the Centers for Disease Control and Prevention

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss changes in the epidemiology of fungal diseases in children
  • outline advances in the diagnosis of invasive fungal diseases
  • describe optimal use of antifungal agents in children
  • identify an optimized approach to the prevention and management of invasive candidiasis in neonates

Target Audience: Scientists, Researchers, Public Health Practitioners, Pharmacists, Microbiologists, Lab Personnel, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Hospital Epidemiologists, Health Care Workers, Fellows-in-Training, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Epidemiology and Infection Control, Pediatric ID

Moderators:  Theoklis Zaoutis, MD, MSCE, The Children's Hospital of Philadelphia and Tom Chiller, MD, MPH, Centers for Disease Control and Prevention

Presentations:

8:30 AM
68
Changes in Epidemiology
Tom Chiller, MD, MPH

8:50 AM
69

9:15 AM
70
Antifungal Agents in Children
William Steinbach, MD, FIDSA

9:35 AM
71

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM possible

Disclosures:

T. Zaoutis, Merck: Consultant and Grant Investigator, Consulting fee, Grant recipient and Speaker honorarium
Astellas: Consultant, Consulting fee
Pfizer: Consultant, Consulting fee

T. Chiller, None

T. Chiller, None

T. Zaoutis, Merck: Consultant and Grant Investigator, Consulting fee, Grant recipient and Speaker honorarium
Astellas: Consultant, Consulting fee
Pfizer: Consultant, Consulting fee

W. Steinbach, Astellas: Scientific Advisor, Research grant
Merck: Scientific Advisor, Research grant
Pfizer: Speaker's Bureau, Speaker honorarium

D. A. Kaufman, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.